Exploratory trial on sphingolipid for the discovery of novel cancer biomarker
- Conditions
- gastric cancer, esophageal cancer, soft tissue sarcoma
- Registration Number
- JPRN-UMIN000007892
- Lead Sponsor
- Institute of Development, Aging and Cancer Tohoku University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 30
Not provided
1) with active infection (more than 38 degree) 2) with the following heart disorder or state ->A history of previous congestive heart failure ->High-risk cardiac arrhythmia that is impossible to control ->Clinical serious heart valve disease ->Hypertension (e.g. patients with systolic blood pressure> 180mmHg or diastolic blood pressure> 100mmHg) 3) with serious complications (interstitial pneumonia, pulmonary fibrosis, heart failure, renal failure, hepatic failure or diabetes mellitus inadequate control) 4) with active bleeding from gastric cancer, esophageal cancer or gastrointestinal ulcer 5) with multiple primary cancer keeping activity 6) receiving systemic steroid therapy continuously 7) A pregnant woman or woman with pregnant possibility 8) Doctor's decision not to be registered to this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We examine the utility of S1P as novel tumor marker.
- Secondary Outcome Measures
Name Time Method We examine correlation between S1P value and response rate(RR), progression-free survival(PFS) and overall survival(OS).